Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Point Mutations Effects on Charge Transport Properties of the Tumor-Suppressor Gene p53

Electric Transport Properties of the p53 Gene and the Effects of Point Mutations

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

The interplay of mutations and electronic properties in disease-related genes

[Advances on Mutant P53 Research].

Modeling the Etiology of p53-mutated Cancer Cells

Unraveling The Allosteric Mechanism Of Four Cancer-Related Mutations In The Disruption Of P53-Dna Interaction

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

Gain of Function of P53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways

Integrating mutation data and structural analysis of the TP53 tumor‐suppressor protein

In Silico Screening, Molecular Dynamics Simulation and Binding Free Energy Identify Single-Point Mutations That Destabilize p53 and Reduce Binding to DNA

A review on point mutations via proton transfer in DNA base pairs in the absence and presence of electric fields

Bioinformatics study of cancer-related mutations within p53 phosphorylation site motifs.

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

P53 Gain-of-Function: Tumor Biology and Bioinformatics Come Together

Navigating the complexity of p53-DNA binding: implications for cancer therapy

Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy